BRANFORD, Conn., June 17, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that seven abstracts were presented at Euroanaesthesia 2010, the annual meeting of the European Society of Anaesthesia, on June 12-15 in Helsinki, Finland, demonstrating the value of measuring cerebral oxygen saturation (SctO2) with the FORE-SIGHT® Absolute Oximeter.
The studies were conducted by Professors Cathy DeDeyne, René Heylen and colleagues in the Department of Anaesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium. Preliminary results from these studies highlighted the utility of monitoring SctO2 with FORE-SIGHT during various procedures including orthopedic surgery performed in the "beach chair" position. This observational study showed significantly lower cerebral oxygen saturations in patients undergoing surgery in the beach chair position when compared to patients in the conventional (side) positioning, while no significant differences were observed in other standard physiologic parameters. Thus, FORE-SIGHT detected poor brain oxygenation that would have been missed with routine monitoring.
Two additional studies highlighted the use of FORE-SIGHT during and after carotid endarterectomy procedures (surgical procedure removing plaque in the carotid arteries). In this study of 172 patients, the researchers observed significant differences between right and left brain SctO2 values after carotid clamping. Results also indicated an increased requirement for shunt insertion on those patients with SctO2 values below a threshold of 55% after carotid clamping. In a postoperative study of 24 endarterectomy patients, researchers observed that one third of these patients had significant increases in SctO2 on the side of the brain receiving the carotid surgery.
Additional studies observed a link between changes in SctO2 and various physiological events, including induced changes in end tidal carbon dioxide; induction of general anesthesia; moderate hypoxic arterial events; and cardiopulmonary rescuscitation (CPR).
Andrew Kersey, President and CEO of CASMED, commented, "The presentation of these studies at an important meeting like Euroanaesthesia 2010 promotes the value of our FORE-SIGHT technology to a worldwide audience. Ziekenhuis Oost-Limburg in Genk, Belgium is a key research institution for CASMED in the European medical community, and we are pleased with their continuing contributions as a Center of Excellence for FORE-SIGHT."
References
(1) DeBurghgraeve F, DeDeyne C, Truijen J, Vandermeersch E, Heylen R. Cerebrovascular reactivity (by CO2 challenge) can be monitored by non-invasive absolute cerebral oxygen saturation (FORE-SIGHT Technology). Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP8-4.
(2) DeBurghgraeve F, DeDeyne C, Oosterbosch J, Vandermeersch E, Heylen R. Monitoring of absolute cerebral oxygen saturation (FORE-SIGHT Technology) during endoscopic shoulder surgery: beach chair positioning or conventional side positioning. Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP8-1.
(3) Ramakers F, DeDeyne C, Jans F, Vandermeersch E, Heylen R. New technology of non-invasive cerebral oximetry (FORE-SIGHT Technology) to monitor cerebral perfusion during resuscitation from cardiac arrest (CPR). Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP6-11.
(4) DeNaeyer S, DeDeyne C, Lansink W, Vercauteren M, Heylen R. Non-invasive absolute cerebral oximetry (FORE-SIGHT Technology) during carotid endarterectomy. Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP6-10.
(5) Beran M, DeDeyne C, Lauwers G, Jans F, Heylen R. Postoperative monitoring of non-invasive cerebral oxygen saturation after carotid endarterectomy. Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP8-3.
(6) Prihadi E, DeDeyne C, Truijen J, Jans F, Heylen R. Acute peripheral oxygen desaturation does not result in significant decreases in cerebral oxygen saturation. Eur J Anaesthesiol 2010; 27 (Suppl 47): 7AP4-7.
(7) DeNaeyer S, DeDeyne C, Jans F, Vercauteren M, Heylen R. Monitoring of absolute cerebral oxygen saturation during induction of general anesthesia. Eur J Anaesthesiol 2010; 27 (Suppl 47): 3AP8-2.
About CASMED® - Monitoring What's Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.
The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.